References
- Corriveau A. Cancer incidence and mortality in theNWT 1991 to 1996. Epi-North 1997; 9 (2): 5.
- McCrory DC, Matchar DB, Bastian L, et al. Evaluation of Cervical Cytology. Evidence Report/ Technology Assessment No. 5.AHCPR Publication No. 99-E010. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Rockville, MD, February 1999.
- Healey SM, Aronson KJ, Mao Y, Franco. Oncogenic Human Papillomavirus Infection and Cervical Lesions in Aboriginal Women in Nunavut, Canada. Sexually Transmitted Diseases 200128 (12): 694–700
- Ratnam S, Franco EL, Ferenczy A. Human papilloma-virus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomark Prey 2000; 9: 945–951.
- Sellors JW, Mahony JB, Kaczorowski J, et al. Preva-lence and predictors of human papillomavirus infection in women in Ontario, Canada. Can Med Assoc J 2000; 163: 503–508.
- Liaw K, Glass A, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Can lnst 1999; 9: 954–60.
- Rosendaal L, Westerga J, van der Linden JC, et al. PCR-based high-risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000; 53: 606–611.